<DOC>
	<DOCNO>NCT00304642</DOCNO>
	<brief_summary>Approximately 18 woman enrol single-center , double-blind , randomized Phase I study assess vaginal tissue fluid level , plasma level pharmacokinetics dapivirine ( TMC120 ) gel , apply 10 consecutive day 18 healthy HIV-negative woman age 18 50 . Volunteers randomize 1:1:1 ratio receive 2.5mL dapivirine vaginal microbicide gel one three concentration .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetics Dapivirine ( TMC120 ) Vaginal Microbicide Gel</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>HIVnegative Willing participate sign informed consent form . Willing test HIV use experimental vaginal gel . Willing use reliable form contraception study . Willing undergo pelvic examination colposcopy accord protocol throughout study . Normal cervical assessment . Willing abstain use vaginal product ( study product ) . Willing sexually abstinent Day 1 completion study product use Day 10 . Currently pregnant breastfeeding . Currently clinically detectable abnormality vulva , vaginal wall cervix . Currently laboratory confirm gonorrhea , chlamydia , trichomonas syphilis , Genital Ulcer Disease ( GUD ) vaginal candidiasis symptom ; HSV2 lesion indicate clinical diagnosis laboratory test . Symptomatic bacterial vaginosis ( BV ) unwilling undergo treatment . Current use injection drug .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>